Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Isolation of secreted proteins from Drosophila ovaries and embryos through in vivo BirA-mediated biotinylation.

Stevens LM, Zhang Y, Volnov Y, Chen G, Stein DS.

PLoS One. 2019 Oct 28;14(10):e0219878. doi: 10.1371/journal.pone.0219878. eCollection 2019.

2.

A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine.

Leong FJ, Jain JP, Feng Y, Goswami B, Stein DS.

Malar J. 2018 Jan 5;17(1):7. doi: 10.1186/s12936-017-2162-8.

3.

Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers.

Jain JP, Leong FJ, Chen L, Kalluri S, Koradia V, Stein DS, Wolf MC, Sunkara G, Kota J.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00868-17. doi: 10.1128/AAC.00868-17. Print 2017 Sep.

4.

Developmental Regression, Depression, and Psychosocial Stress in an Adolescent with Down Syndrome.

Stein DS, Munir KM, Karweck AJ, Davidson EJ, Stein MT.

J Dev Behav Pediatr. 2017 Feb/Mar;38 Suppl 1:S26-S28. doi: 10.1097/DBP.0000000000000401.

5.

Reconstitution of Torso signaling in cultured cells suggests a role for both Trunk and Torso-like in receptor activation.

Amarnath S, Stevens LM, Stein DS.

Development. 2017 Feb 15;144(4):677-686. doi: 10.1242/dev.146076. Epub 2017 Jan 13.

6.

Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects.

Sun H, Ting L, Machineni S, Praestgaard J, Kuemmell A, Stein DS, Sunkara G, Kovacs SJ, Villano S, Tanaka SK.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7431-7435. Print 2016 Dec.

7.

Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline.

Flarakos J, Du Y, Gu H, Wang L, Einolf HJ, Chun DY, Zhu B, Alexander N, Natrillo A, Hanna I, Ting L, Zhou W, Dole K, Sun H, Kovacs SJ, Stein DS, Tanaka SK, Villano S, Mangold JB.

Xenobiotica. 2017 Aug;47(8):682-696. doi: 10.1080/00498254.2016.1213465. Epub 2016 Aug 8.

PMID:
27499331
8.

KAE609 (Cipargamin), a New Spiroindolone Agent for the Treatment of Malaria: Evaluation of the Absorption, Distribution, Metabolism, and Excretion of a Single Oral 300-mg Dose of [14C]KAE609 in Healthy Male Subjects.

Huskey SE, Zhu CQ, Fredenhagen A, Kühnöl J, Luneau A, Jian Z, Yang Z, Miao Z, Yang F, Jain JP, Sunkara G, Mangold JB, Stein DS.

Drug Metab Dispos. 2016 May;44(5):672-82. doi: 10.1124/dmd.115.069187. Epub 2016 Feb 26.

PMID:
26921387
9.

Open-label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine.

Stein DS, Jain JP, Kangas M, Lefèvre G, Machineni S, Griffin P, Lickliter J.

Antimicrob Agents Chemother. 2015;59(6):3493-500. doi: 10.1128/AAC.00340-15. Epub 2015 Apr 6.

10.

Autism associated with early institutionalization, high intelligence, and naturalistic behavior therapy in a 7-year-old boy.

Stein DS, Welchons LW, Corley KB, Dickinson H, Levin AR, Nelson CA, Stein MT.

J Dev Behav Pediatr. 2015 Jan;36(1):53-5. doi: 10.1097/DBP.0000000000000120.

PMID:
25539091
11.

"Complex" attention-deficit hyperactivity disorder, more norm than exception? Diagnoses and comorbidities in a developmental clinic.

Koolwijk I, Stein DS, Chan E, Powell C, Driscoll K, Barbaresi WJ.

J Dev Behav Pediatr. 2014 Nov-Dec;35(9):591-7. doi: 10.1097/DBP.0000000000000109.

PMID:
25343695
12.

Maternal control of the Drosophila dorsal-ventral body axis.

Stein DS, Stevens LM.

Wiley Interdiscip Rev Dev Biol. 2014 Sep-Oct;3(5):301-30. doi: 10.1002/wdev.138. Epub 2014 May 29. Review.

13.

Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection.

Colvin RA, Tanwandee T, Piratvisuth T, Thongsawat S, Hui AJ, Zhang H, Ren H, Chen PJ, Chuang WL, Sobhonslidsuk A, Li R, Qi Y, Praestgaard J, Han Y, Xu J, Stein DS; ABF656A2206 Study Group.

J Gastroenterol Hepatol. 2015 Jan;30(1):184-91. doi: 10.1111/jgh.12671.

PMID:
24995515
14.

Teaching adults-best practices that leverage the emerging understanding of the neurobiology of learning.

Mahan JD, Stein DS.

Curr Probl Pediatr Adolesc Health Care. 2014 Jul;44(6):141-9. doi: 10.1016/j.cppeds.2014.01.003. Review.

PMID:
24981663
15.

Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period study.

Lefèvre G, Bhad P, Jain JP, Kalluri S, Cheng Y, Dave H, Stein DS.

Malar J. 2013 Sep 8;12:312. doi: 10.1186/1475-2875-12-312.

16.

Phase I, open-label, single-dose study to evaluate the pharmacokinetics and safety of telbivudine in children and adolescents with chronic hepatitis B.

Stein DS, Ke J, Uy G, Bosheva M, Qi Y, Praestgaard J; LDT600A2104 Study Team.

Antimicrob Agents Chemother. 2013 Sep;57(9):4128-33. doi: 10.1128/AAC.00117-13. Epub 2013 Jun 17.

17.

Developmental regression, depression, and psychosocial stress in an adolescent with Down syndrome.

Stein DS, Munir KM, Karweck AJ, Davidson EJ, Stein MT.

J Dev Behav Pediatr. 2013 Apr;34(3):216-8. doi: 10.1097/DBP.0b013e31828b2b42.

18.

Disposition and metabolism of [¹⁴C]PTZ601 in healthy volunteers.

Flarakos J, Ting LS, Du Y, Stein DS, Reynolds CV, Patel M, Roy S, Mangold JB.

Xenobiotica. 2013 Mar;43(3):283-92. doi: 10.3109/00498254.2012.715696. Epub 2012 Aug 29.

PMID:
22931187
19.

Developmental and behavioral disorders through the life span.

Stein DS, Blum NJ, Barbaresi WJ.

Pediatrics. 2011 Aug;128(2):364-73. doi: 10.1542/peds.2011-0266. Epub 2011 Jul 18. Review.

PMID:
21768324
20.

Population pharmacokinetics and exposure-response of albinterferon alfa-2b.

Riggs MM, Bergsma TT, Rogers JA, Gastonguay MR, Subramanian GM, Chen C, Devalaraja M, Corey AE, Sun H, Yu J, Stein DS.

J Clin Pharmacol. 2012 Apr;52(4):475-86. doi: 10.1177/0091270011399576. Epub 2011 May 6.

PMID:
21551316
21.

Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis.

Louie A, Stein DS, Zack JZ, Liu W, Conde H, Fregeau C, Vanscoy BD, Drusano GL.

Antimicrob Agents Chemother. 2011 Jul;55(7):3295-304. doi: 10.1128/AAC.01324-10. Epub 2011 Apr 18.

22.

Single-dose pharmacokinetics, safety, and tolerability of albinterferon alfa-2b in subjects with end-stage renal disease on hemodialysis compared to those in matched healthy volunteers.

Serra DB, Sun H, Karwowska S, Praestgaard J, Halabi A, Stein DS.

Antimicrob Agents Chemother. 2011 Feb;55(2):473-7. doi: 10.1128/AAC.00626-10. Epub 2010 Nov 22.

23.

Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.

DeJesus E, Piliero PJ, Summers K, Wire MB, Stein DS, Masterman A, Lou Y, Min SS, Shelton MJ.

Antimicrob Agents Chemother. 2006 Sep;50(9):3157-9.

24.

Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity.

Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS.

J Infect Dis. 2006 Aug 15;194(4):486-92. Epub 2006 Jul 10.

PMID:
16845632
25.

Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor.

Ford SL, Reddy YS, Anderson MT, Murray SC, Fernandez P, Stein DS, Johnson MA.

Antimicrob Agents Chemother. 2006 Jun;50(6):2201-6.

26.

Mis-specified cells die by an active gene-directed process, and inhibition of this death results in cell fate transformation in Drosophila.

Werz C, Lee TV, Lee PL, Lackey M, Bolduc C, Stein DS, Bergmann A.

Development. 2005 Dec;132(24):5343-52. Epub 2005 Nov 9.

27.

Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir.

Ford SL, Wire MB, Lou Y, Baker KL, Stein DS.

Antimicrob Agents Chemother. 2005 Jan;49(1):467-9.

28.

Pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1-infected children.

Stein DS, Lou Y, Johnson M, Randall S, Blanche S; Prob2004 Study Team.

J Clin Pharmacol. 2004 Nov;44(11):1301-8.

PMID:
15496648
29.

Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers.

Wire MB, Ballow C, Preston SL, Hendrix CW, Piliero PJ, Lou Y, Stein DS.

AIDS. 2004 Apr 9;18(6):897-907.

PMID:
15060437
30.

Disease progression in HIV-infected patients treated with stavudine vs. zidovudine.

Justice AC, Stein DS, Fusco GP, Sherrill BH, Fusco JS, Danehower SC, Becker SL, Hansen NI, Graham NM; CHORUS Program Team.

J Clin Epidemiol. 2004 Jan;57(1):89-97.

PMID:
15019015
31.
32.

Functional characterization and expression analysis of members of the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase family from Drosophila melanogaster.

Ten Hagen KG, Tran DT, Gerken TA, Stein DS, Zhang Z.

J Biol Chem. 2003 Sep 12;278(37):35039-48. Epub 2003 Jun 26.

33.
34.

Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.

Sale M, Sadler BM, Stein DS.

Antimicrob Agents Chemother. 2002 Mar;46(3):746-54.

35.

Clinical pharmacology and pharmacokinetics of amprenavir.

Sadler BM, Stein DS.

Ann Pharmacother. 2002 Jan;36(1):102-18. Review.

PMID:
11816239
36.

Pharmacodynamics of abacavir in an in vitro hollow-fiber model system.

Drusano GL, Bilello PA, Symonds WT, Stein DS, McDowell J, Bye A, Bilello JA.

Antimicrob Agents Chemother. 2002 Feb;46(2):464-70.

37.

Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.

Sadler BM, Gillotin C, Lou Y, Eron JJ, Lang W, Haubrich R, Stein DS.

Antimicrob Agents Chemother. 2001 Dec;45(12):3663-8.

38.
39.

Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.

Sadler BM, Piliero PJ, Preston SL, Lloyd PP, Lou Y, Stein DS.

AIDS. 2001 May 25;15(8):1009-18.

PMID:
11399983
40.

Increased incidence of sepsis and altered monocyte functions in severely injured type A- glucose-6-phosphate dehydrogenase-deficient African American trauma patients.

Spolarics Z, Siddiqi M, Siegel JH, Garcia ZC, Stein DS, Ong H, Livingston DH, Denny T, Deitch EA.

Crit Care Med. 2001 Apr;29(4):728-36.

PMID:
11373456
41.

Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects.

Sadler BM, Chittick GE, Polk RE, Slain D, Kerkering TM, Studenberg SD, Lou Y, Moore KH, Woolley JL, Stein DS.

J Clin Pharmacol. 2001 Apr;41(4):386-96.

PMID:
11304895
42.

Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians.

Stein DS, Moore KH.

Pharmacotherapy. 2001 Jan;21(1):11-34. Review.

PMID:
11191730
43.
44.

Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.

Polk RE, Brophy DF, Israel DS, Patron R, Sadler BM, Chittick GE, Symonds WT, Lou Y, Kristoff D, Stein DS.

Antimicrob Agents Chemother. 2001 Feb;45(2):502-8.

45.
46.
48.

Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation.

Peng AW, Milleri S, Stein DS.

Antimicrob Agents Chemother. 2000 Jul;44(7):1974-6.

49.

Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults.

McDowell JA, Chittick GE, Stevens CP, Edwards KD, Stein DS.

Antimicrob Agents Chemother. 2000 Jun;44(6):1686-90.

50.

Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function.

Veronese L, Rautaureau J, Sadler BM, Gillotin C, Petite JP, Pillegand B, Delvaux M, Masliah C, Fosse S, Lou Y, Stein DS.

Antimicrob Agents Chemother. 2000 Apr;44(4):821-6.

Supplemental Content

Loading ...
Support Center